Tebipenem pivoxil hydrobromide (SPR994)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tebipenem pivoxil hydrobromide (SPR994), covering 2022-07-25 to 2022-07-25. Get the full timeline:
Most recent: Clinical Trial Update: Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) [Phase 3]